Osimertinib With or Without Bevacizumab for Patients With EGFR-Mutant Lung Cancer

Short Title: EA5182

Enrollment Status: Recruiting

NCT #: NCT04181060

Specialty Area: Oncology

Condition Studied: Advanced Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To compare the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with non-squamous Non-small Cell Lung Cancer (NSCLC)
Cancer must be EGFR-mutated
Cannot be pregnant or breastfeeding
No prior treatment to block Vascular Endothelial Growth Factor (VEGF) or for advanced lung cancer
No serious heart problems or tumors invading major blood vessels

What's Involved

Participation in the study will include:

Treatment with Osimertinib given orally with or without Bevacizumab given intravenously (IV)
CT/MRI scan
Echocardiography test
Multigated Acquisition (MUGA) Scan
Blood and urine samples

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT04181060

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews